TR201707764A2 - Deferasiroksun bölünebilir tablet formları. - Google Patents

Deferasiroksun bölünebilir tablet formları. Download PDF

Info

Publication number
TR201707764A2
TR201707764A2 TR2017/07764A TR201707764A TR201707764A2 TR 201707764 A2 TR201707764 A2 TR 201707764A2 TR 2017/07764 A TR2017/07764 A TR 2017/07764A TR 201707764 A TR201707764 A TR 201707764A TR 201707764 A2 TR201707764 A2 TR 201707764A2
Authority
TR
Turkey
Prior art keywords
deferasirox
tablet forms
split tablet
split
forms
Prior art date
Application number
TR2017/07764A
Other languages
English (en)
Inventor
Kandemi̇rer Ürün
Çi̇fter Ümi̇t
Yazici Gülnur
Original Assignee
Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to TR2017/07764A priority Critical patent/TR201707764A2/tr
Priority to PCT/TR2018/050241 priority patent/WO2019004985A2/en
Publication of TR201707764A2 publication Critical patent/TR201707764A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Buluş, vücutta aşırı miktarda demir birikimi ile ortaya çıkan durumların tedavisinde kullanılmak üzere; deferasiroksun veya onun farmasötik olarak kabul edilebilir bir tuzunun bölünebilir tablet formları ile ilgilidir.
TR2017/07764A 2017-05-29 2017-05-29 Deferasiroksun bölünebilir tablet formları. TR201707764A2 (tr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2017/07764A TR201707764A2 (tr) 2017-05-29 2017-05-29 Deferasiroksun bölünebilir tablet formları.
PCT/TR2018/050241 WO2019004985A2 (en) 2017-05-29 2018-05-17 FORMS IN SECRET TABLETS OF DEFERASIROX

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2017/07764A TR201707764A2 (tr) 2017-05-29 2017-05-29 Deferasiroksun bölünebilir tablet formları.

Publications (1)

Publication Number Publication Date
TR201707764A2 true TR201707764A2 (tr) 2018-12-21

Family

ID=64742490

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2017/07764A TR201707764A2 (tr) 2017-05-29 2017-05-29 Deferasiroksun bölünebilir tablet formları.

Country Status (2)

Country Link
TR (1) TR201707764A2 (tr)
WO (1) WO2019004985A2 (tr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
CA2713128C (en) * 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
SG11201506491RA (en) * 2013-03-08 2015-09-29 Novartis Ag Oral formulations of deferasirox

Also Published As

Publication number Publication date
WO2019004985A2 (en) 2019-01-03
WO2019004985A3 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
JOP20210105B1 (ar) مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp
SA520411125B1 (ar) Nlrp مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط
MX2022002579A (es) Compuestos de aminotiazol como inhibidores de c- kit.
CL2018002698A1 (es) Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a
NZ736665A (en) Heterocyclic amides as kinase inhibitors
MX2015014582A (es) Agentes para regulacion hacia abajo de la actividad y/o cantidad de bcl-xl y/o bcl-w.
MX386598B (es) Compuestos antibacterianos.
BR112015019627A2 (pt) amidas heterocíclicas como inibidores de quinases
PH12017502142A1 (en) Tetrasubstituted aklene compounds and their use
TW201613872A (en) IRAK4 inhibiting agents
TR201808169T3 (tr) Rekombinant probiyotik bakteriler .
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
PH12017500095A1 (en) Imidazopyridazine compounds
BR112017000730B8 (pt) Derivados de pirrolidinona como inibidores de metap-2, e medicamentos
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
EP4501406A3 (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
MX2020008195A (es) Compuestos para el tratamiento del dolor.
MX2019007826A (es) Activador nrf2.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
EA201890212A1 (ru) Новое применение сульфата декстрана
MX2018002018A (es) Derivado de urea y uso del mismo.
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
MX2020003575A (es) Nuevos derivados de alcoxiamino para tratar dolor y estados relacionados con dolor.
MX375860B (es) Uso de 2-(5s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida en el tratamiento de convulsiones.
TR201718945A2 (tr) Deferasiroks içeren farmasötik ürün için bir üretim yöntemi.